1.
Journal of Experimental Hematology
;
(6): 636-640, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-928767
ABSTRACT
Hemolytic uremic syndrome (HUS) is clinically rare, with high mortality and case fatality rates. In recent years, the research on HUS has been intensified and the pathophysiological mechanism has been continuously improved. At present, the main mechanism of pathogenesis is the excessive activation of complement alternative pathways mediated by complement-related gene mutations or the existence of antibodies. The treatment methods and strategies are also constantly updated, mainly including complement-blocking drugs such as Eculizumab, Lavalizumab, and Ravulizumab. In this review, the new developments in the pathogenesis and treatment of HUS is summarized, and provide references for the clinical treatment of HUS.
Subject(s)
Humans , Complement System Proteins/therapeutic use , Hemolytic-Uremic Syndrome/therapy , Mutation
2.
Reumatología (Santiago de Chile)
;
12(4): 137-40, 1996. ilus, tab
Article
in Spanish
| LILACS
| ID: lil-210459